Immunotherapeutic Vaccine Candidate Fast Tracked for Alzheimer Disease
UB-311 is an immunotherapeutic vaccine candidate that targets toxic forms of aggregated amyloid beta in the brain.
UB-311 is an immunotherapeutic vaccine candidate that targets toxic forms of aggregated amyloid beta in the brain.
Among patients with cognitive symptoms, choroid plexus volume is associated with the stage of cognitive impairment.
Researchers sought to examine the association between the number of important subcortical wake-promoting neurons and clinical sleep phenotypes in patients with AD or PSP.
Midlife obesity, physical inactivity, and low education are the three most prominent modifiable risk factors associated with ADRDs.
Multidomain interventions are equally effective for improving cognition in women and men.
From 2004 to 2017, there was an increase in the percentage of US older adult decedents with a diagnosis of Alzheimer disease and related dementias (ADRD).
In a cross-sectional study, researchers compared COVID-19 infection and mortality rates from 2019 and 2020 among Medicare enrollees with Alzheimer disease and related dementias.
Male mice were exposed to chronic stress using a social defeat stress experiment. Mice were assessed for behavioral deviations and impacts to motor learning after the stress experiment as well as neural changes due to stress.
Excessive daytime napping predicts an increased future risk of Alzheimer dementia, and a diagnosis of Alzheimer dementia increases daytime napping during aging.
Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion.